Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions

Glycoconjugate Journal

Volumn 33, Issue 4, 2016, Pages 607-617

  Neviere, Remi ^a,b   Yu, Yichi ^b,c   Wang, Lei ^b,c   Tessier, Frederic ^b   Boulanger, Eric ^b  

^a Institut Fédératif de Recherche 114   (France)

^b UNIV LILLE   (France)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced glycation end products; Cardiovascular; Mitochondria; Signaling pathways

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; AGER PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BASEMENT MEMBRANE; CALCIUM CELL LEVEL; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CROSS LINKING; DIETARY INTAKE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXTRACELLULAR MATRIX; FIBROSIS; GENE ACTIVATION; GLYCATION; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE COMPLIANCE; HUMAN; INFLAMMATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL ENERGY TRANSFER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INTERACTION; UPREGULATION; CARDIAC MUSCLE; HEART MITOCHONDRION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; GLYCATION END PRODUCTS, ADVANCED; HUMANS; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATIVE STRESS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS;

EID: 84976321291     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-016-9679-x     Document Type: Article

References (103)

1. Poulsen M.W., Hedegaard R.V., Andersen J.M., de Courten B., Bügel S., Nielsen J., et al.: Advanced glycation endproducts in food and their effects on health. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 60, 10–37 (2013)
2. Ott C., Jacobs K., Haucke E., Navarrete Santos A., Grune T., Simm A.: Role of advanced glycation end products in cellular signaling. Redox Biol. 2, 411–429 (2014)
3. Boulanger E., Wautier M.P., Wautier J.L., Boval B., Panis Y., Wernert N., Danze P.M., Dequiedt P.: AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int. 61, 148–156 (2002)
4. Boulanger E., Grossin N., Wautier M.P., Taamma R., Wautier J.L.: Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int. 71, 126–133 (2007)
5. Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D’Agati VD, Schmidt AM, Boulanger E.: Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabete Metab. 36, 1–10 (2010)
6. Zhao J., Randive R., Stewart J.A.: Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. World J. Diabetes. 6, 860–867 (2014)
7. Ramasamy R., Schmidt A.M.: Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr. Heart Fail. Rep. 2, 107–116 (2012)
8. Barlovic D.P., Soro-Paavonen A., Jandeleit-Dahm K.A.M.: RAGE biology, atherosclerosis and diabetes. Clin. Sci. Lond. Engl. 121, 43–55 (2011)
9. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., Kaneko M., Song F., Sell D.R., et al.: RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 57, 1941–1951 (2004)
10. Bucciarelli L.G., Kaneko M., Ananthakrishnan R., Harja E., Lee L.K., Hwang Y.C., et al.: Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 113, 1226–1234 (2006)
11. Shang L., Ananthakrishnan R., Li Q., Quadri N., Abdillahi M., Zhu Z., et al.: RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS ONE. 4, e10092 (2010)
12. Nielsen J.M., Kristiansen S.B., Nørregaard R., Andersen C.L., Denner L., Nielsen T.T., et al.: Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur. J. Heart Fail. 11, 638–647 (2009)
13. Fukami K., Yamagishi S.-I., Okuda S.: Role of AGEs-RAGE system in cardiovascular disease. Curr. Pharm. Des. 20, 2395–2402 (2014)
14. Schmidt A.M.: Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. Vasc. Pharmacol. 72, 1–8 (2015)
15. Yamagishi S., Matsui T.: NakamuraK.: Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets. 8, 1138–1143 (2007)
16. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., et al.: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22, 3716–3727 (2008)
17. Koyama Y., Takeishi Y., Niizeki T., Suzuki S., Kitahara T., Sasaki T., Kubota I.: Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J. Card. Fail. 14, 133–139 (2008)
18. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D.C., Kashyap Y., Stern D.M., Schmidt A.M.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 106, 2827–2835 (2002)
19. Nakamura K., Adachi H., Matsui T., Kurita Y., Takeuchi M., Yamagishi S.: Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism. 58, 421–425 (2009)
20. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., Imaizumi T.: Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 70, 137–141 (2005)
21. Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R.: Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 23, 1725–1729 (2005)
22. Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D.: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25, 1032–1037 (2005)
23. Mahajan N., Malik N., Bahl A., Dhawan V.: Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 207(2), 597–602 (2009)
24. Mulder D.J., van Haelst P.L., Gross S., de Leeuw K., Bijzet J., Graaff R., et al.: Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis. 197, 217–223 (2008)
25. Raposeiras-Roubín S., Rodiño-Janeiro B.K., Grigorian-Shamagian L., Moure-González M., Seoane-Blanco A., Varela-Román A., et al.: Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am. J. Cardiol. 107, 938–944 (2011)
26. Raposeiras-Roubín S., Rodiño-Janeiro B.K., Grigorian-Shamagian L., Moure-González M., Seoane-Blanco A., Varela-Román A., et al.: Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur. J. Heart Fail. 12, 1092–1100 (2010)
27. Raposeiras-Roubín S., Rodiño-Janeiro B.K., Grigorian-Shamagian L., Seoane-Blanco A., Moure-González M., Varela-Román A., et al.: Evidence for a role of advanced glycation end products in atrial fibrillation. Int. J. Cardiol. 157, 397–402 (2012)
28. Basta G., Leonardis D., Mallamaci F., Cutrupi S., Pizzini P., Gaetano L., et al.: Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 77, 225–231 (2010)
29. Kim J.K., Park S., Lee M.J., Song Y.R., Han S.H., Kim S.G., et al.: Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 220, 208–214 (2012)
30. Leonardis D., Basta G., Mallamaci F., Cutrupi S., Pizzini P., Tripepi R., Tripepi G., De Caterina R., Zoccali C., et al.: Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr. Metab. Cardiovasc. Dis. 22, 748–755 (2012)
31. Prasad K.: Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int. J. Angiol. 23, 11–16 (2014)
32. Selvin E., Halushka M.K., Rawlings A.M., Hoogeveen R.C., Ballantyne C.M., Coresh J., et al.: sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 62, 2116–2121 (2013)
33. Yan S.F., Ramasamy R., Schmidt A.M.: The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. Mar. 106, 842–853 (2010)
34. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., et al.: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143, 1699–1712 (1993)
35. Donaldson C., Taatjes D.J., Zile M., Palmer B., VanBuren P., Spinale F., et al.: Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem. Cell Biol. 134, 23–30 (2010)
36. Willemsen S., Hartog J.W.L., Heiner-Fokkema M.R., van Veldhuisen D.J., Voors A.A.: Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail. Rev. 17, 221–228 (2012)
37. Smit A.J., Hartog J.W.L., Voors A.A., van Veldhuisen D.J.: Advanced glycation endproducts in chronic heart failure. Ann. N. Y. Acad. Sci. 1126, 225–230 (2008)
38. Hartog J.W.L., Voors A.A., Bakker S.J.L., Smit A.J., van Veldhuisen D.J.: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 9, 1146–1155 (2007)
39. Campbell D.J., Somaratne J.B., Jenkins A.J., Prior D.L., Yii M., Kenny J.F., et al.: Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc. Diabetol. 10, 80–86 (2011)
40. Nożyński J., Zakliczyński M., Konecka-Mrowka D., Zielinska T., Zakliczynska H., Nikiel B., et al.: Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann. Transplant. Q. Pol. Transplant. Soc. 17, 53–61 (2012)
41. Nenna A., Nappi F., Avtaar Singh S.S., Sutherland F.W., Di Domenico F., Chello M., Spadaccio C.: Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res. Cardiovasc. Med. 4, e26949 (2015)
42. Engelen L., Stehouwer C.D., Schalkwijk C.G.: Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes. Metab. 15, 677–689 (2013)
43. Bolton W.K., Cattran D.C., Williams M.E., Adler S.G., Appel G.B., Cartwright K., Foiles P.G., Freedman B.I., Raskin P., Ratner R.E., Spinowitz B.S., Whittier F.C., Wuerth J.P., ACTION I Investigator Group., et al.: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32–40 (2004)
44. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A.: deGroof RC, Lakatta EG.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 104, 1464–1470 (2001)
45. Hartog J.W.L., Willemsen S., van Veldhuisen D.J., Posma J.L., van Wijk L.M., Hummel Y.M., et al.: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur. J. Heart Fail. 13, 899–908 (2011)
46. Zieman S.J., Melenovsky V., Clattenburg L., Corretti M.C., Capriotti A., Gerstenblith G., et al.: Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J. Hypertens. 25, 577–583 (2007)
47. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11, 191–195 (2005)
48. Willemsen S., Hartog J.W., Hummel Y.M., Posma J.L., van Wijk L.M., van Veldhuisen D.J., Voors A.A.: Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur. J. Heart Fail. 12, 294–300 (2010)
49. Fujimoto N., Hastings J.L., Carrick-Ranson G., Shafer K.M., Shibata S., Bhella P.S., et al.: Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. Circ. Heart Fail. 6, 1155–1164 (2013)
50. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X., Pyzik R., et al.: Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 110, 911–916 (2010)
51. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., et al.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 94, 6474–6479 (1997)
52. Yamagishi S.-I., Matsui T.: Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. Nutrition. 32, 157–165 (2016)
53. Clarke R.E., Dordevic A.L., Tan S.M., Ryan L., Coughlan M.T.: Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials. Nutrients. 8, E125 (2016)
54. Stirban A., Gawlowski T., Roden M.: Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol. Metab. 3, 94–108 (2014)
55. Grossin N., Auger F., Niquet-Leridon C., Durieux N., Montaigne D., Schmidt A.M., et al.: Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol. Nutr. Food Res. 59, 927–938 (2015)
56. Uribarri J., Stirban A., Sander D., Cai W., Negrean M., Buenting C.E., et al.: Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 30, 2579–2582 (2007)
57. Lin R.Y., Reis E.D., Dore A.T., Lu M., Ghodsi N., Fallon J.T., et al.: Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 163, 303–311 (2002)
58. Lin R.Y., Choudhury R.P., Cai W., Lu M., Fallon J.T., Fisher E.A., Vlassara H.: Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 168, 213–220 (2003)
59. Chen S.X., Song T., Zhou S.H., Liu Y.H., Wu S.J., Liu L.Y.: Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Eur. J. Pharmacol. 584, 368–375 (2008)
60. Semba R.D., Gebauer S.K., Baer D.J., Sun K., Turner R., Silber H.A., Taleqawkar S., Ferrucci L., Novotny J.A., et al.: Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J. Nutr. 144, 1037–1042 (2014)
61. Semba R.D., Ang A., Talegawkar S., Crasto C., Dalal M., Jardack P., Traber M.G., Ferrucci L., Arab L., et al.: Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur. J. Clin. Nutr. 66, 3–9 (2012)
62. Chen X., Mori T., Guo Q., Hu C., Ohsaki Y., Yoneki Y., et al.: Carbonyl stress induces hypertension and cardio–renal vascular injury in Dahl salt-sensitive rats. Hypertens. Res. 36, 361–367 (2013)
63. Crisóstomo J., Matafome P., Santos-Silva D., Rodrigues L., Sena C.M., Pereira P., et al.: Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats. Nutr. Metab. Cardiovasc. Dis. 23, 1223–1230 (2013)
64. Kellow N.J., Savige G.S.: Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. Eur. J. Clin. Nutr. 67, 239–248 (2013)
65. Asif M., Egan J., Vasan S., Jyothirmayi G.N., Masurekar M.R., Lopez S., et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. U. S. A. 97, 2809–2813 (2000)
66. van Heerebeek L., Hamdani N., Handoko M.L., Falcao-Pires I., Musters R.J., Kupreishvili K., et al.: Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 117, 43–51 (2008)
67. Aronson D.: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21, 3–12 (2003)
68. Bucala R., Tracey K.J., Cerami A.: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87, 432–438 (1991)
69. Su J., Lucchesi P.A., Gonzalez-Villalobos R.A., Palen D.I., Rezk B.M., Suzuki Y., et al.: Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler. Thromb. Vasc. Biol. 28, 1432–1438 (2008)
70. Sena C.M., Matafome P., Crisóstomo J., Rodrigues L., Fernandes R., Pereira P., et al.: Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol. Res. 65, 497–506 (2012)
71. Xu B., Ji Y., Yao K., Cao Y.-X., Ferro A.: Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin. Sci. Lond. Engl. 109, 439–446 (2005)
72. Xu B., Chibber R., Ruggiero D., Kohner E., Ritter J., Ferro A., et al.: Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 17, 1289–1291 (2003)
73. Prasad K., Dhar I., Caspar-Bell G.: Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease. Int. J. Angiol. 24, 75–80 (2015)
74. Russo I., Frangogiannis N.G.: Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J. Mol. Cell. Cardiol. 90, 84–93 (2015)
75. Thallas-Bonke V., Coughlan M.T., Tan A.L., Harcourt B.E., Morgan P.E., Davies M.J., et al.: Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrol. Carlton Vic. 18, 47–56 (2013)
76. Petrova R., Yamamoto Y., Muraki K., Yonekura H., Sakurai S., Watanabe T., et al.: Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol. 34, 1425–1431 (2002)
77. Yan D., Luo X., Li Y., Liu W., Deng J., Zheng N., et al.: Effects of advanced glycation end products on calcium handling in cardiomyocytes. Cardiology. 129, 75–83 (2014)
78. Ma H., Li S.-Y., Xu P., Babcock S.A., Dolence E.K., Brownlee M., et al.: Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J. Cell. Mol. Med. 13, 1751–1764 (2009)
79. +-ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway. Clin. Exp. Pharmacol. Physiol. 41, 127–133 (2014)
80. Rojas A., Mercadal E., Figueroa H., Morales M.A.: Advanced Glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol. 6, 44–51 (2008)
81. Li S.-Y., Sigmon V.K., Babcock S.A., Ren J.: Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci. 80, 1051–1056 (2007)
82. Ward M.S., Fortheringham A.K., Cooper M.E., Forbes J.M.: Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr. Opin. Pharmacol. 13, 654–661 (2013)
83. Daffu G., del Pozo C.H., O’Shea K.M., Ananthakrishnan R., Ramasamy R., Schmidt A.M.: Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 14, 19,891–19,910 (2013)
84. Wang L., Li Q., Du J., Chen B., Li Q., Huang X., et al.: Advanced glycation end products induce moesin phosphorylation in murine retinal endothelium. Acta Diabetol. 49, 47–55 (2012)
85. Diguet N., Mallat Y., Ladouce R., Clodic G., Prola A., Tritsch E., et al.: Muscle creatine kinase deficiency triggers both actin depolymerization and desmin disorganization by advanced glycation end products in dilated cardiomyopathy. J. Biol. Chem. 286, 35,007–35,019 (2011)
86. Li Z., Zhong Q., Yang T., Xie X., Chen M.: The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc. Diabetol. 12, 141 (2013)
87. Xie J., Méndez J.D., Méndez-Valenzuela V., Aguilar-Hernández M.M.: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25, 2185–2197 (2013)
88. Tsoporis J.N., Izhar S., Leong-Poi H., Desjardins J.-F., Huttunen H.J., Parker T.G.: S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ. Res. 106, 93–101 (2010)
89. Guo C., Zeng X., Song J., Zhang M., Wang H., Xu X., et al.: A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway. Int. J. Mol. Sci. 13, 11,923–11,940 (2012)
90. Jiang X., Guo C., Zeng X., Li H., Chen B., Du F.: A soluble receptor for advanced glycation end-products inhibits myocardial apoptosis induced by ischemia/reperfusion via the JAK2/STAT3 pathway. Apoptosis Int. J. Program. Cell. Death. 20, 1033–1047 (2015)
91. Kang R., Tang D., Schapiro N.E., Livesey K.M., Farkas A., Loughran P., et al.: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 17, 666–676 (2010)
92. Hou X., Hu Z., Xu H., Xu J., Zhang S., Zhong Y., et al.: Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc. Diabetol. 13, 78 (2014)
93. Hu P., Zhou H., Lu M., Dou L., Bo G., Wu J., et al.: Autophagy Plays a Protective Role in Advanced Glycation End Product-Induced Apoptosis in Cardiomyocytes. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 37, 697–706 (2015)
94. Nelson M.B., Swensen A.C., Winden D.R., Bodine J.S., Bikman B.T., Reynolds P.R.: Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-product signaling in a ceramide-dependent manner. Am. J. Physiol. Heart Circ. Physiol. 309, H63–H69 (2015)
95. Bakala H., Hamelin M., Mary J., Borot-Laloi C., Friguet B.: Catalase, a target of glycation damage in rat liver mitochondria with aging. Biochim. Biophys. Acta. 1822, 1527–1534 (2012)
96. Bakala H., Ladouce R., Baraibar M.A., Friguet B.: Differential expression and glycative damage affect specific mitochondrial proteins with aging in rat liver. Biochim. Biophys. Acta. 1832, 2057–2067 (2013)
97. Cai W., Ramdas M., Zhu L., Chen X., Striker G.E., Vlassara H.: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 109, 15,888–15,893 (2012)
98. Cai W., Uribarri J., Zhu L., Chen X., Swamy S., Zhao Z., et al.: Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 111, 4940–4945 (2014)
99. Huang K.-P., Chen C., Hao J., Huang J.-Y., Liu P.-Q., Huang H.-Q.: AGEs-RAGE system down-regulates Sirt1 through the ubiquitin-proteasome pathway to promote FN and TGF-β1 expression in male rat glomerular mesangial cells. Endocrinology. 156, 268–279 (2015)
100. Yu T., Jhun B.S., Yoon Y.: High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid. Redox Signal. 14, 425–437 (2011)
101. Lo M.-C., Chen M.-H., Lee W.-S., Lu C.-I., Chang C.-R., Kao S.-H., et al.: Nε-(carboxymethyl) lysine-induced mitochondrial fission and mitophagy cause decreased insulin secretion from β-cells. Am. J. Physiol. Endocrinol. Metab. 309, E829–E839 (2015)
102. Dorn G.W.: Mitochondrial dynamism and heart disease: changing shape and shaping change. EMBO Mol. Med. 7, 865–877 (2015)
103. Hoshino A., Ariyoshi M., Okawa Y., Kaimoto S., Uchihashi M., Fukai K., et al.: Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic β-cell function in diabetes. Proc. Natl. Acad. Sci. U. S. A. Feb. 111, 3116–3121 (2014)